Management of Daily Fever in SLE Patients Treated with Belimumab and Hydroxychloroquine

Immediate Infection Evaluation (Priority 1)

• Obtain at least two sets of blood cultures, a urine culture, and a chest‑radiograph in any SLE patient with unexplained fever before modifying immunosuppression. 1
• Perform CMV testing in patients receiving immunosuppressive agents (including belimumab) because opportunistic CMV infection can occur. 1
• Screen for severe neutropenia, severe lymphopenia, and low IgG levels, as these laboratory abnormalities are the principal risk factors for infection in SLE. 1
• Do not empirically intensify immunosuppressive therapy solely on the basis of fever without a thorough infectious work‑up. 1

Assessment of Lupus Disease Activity (Concurrent with Infection Work‑up)

• Conduct a systematic organ examination looking for new or worsening cutaneous rash, active arthritis, serositis, neuro‑psychiatric symptoms, or renal involvement. 1
• Persistent low complement C3 with a normal C4 level signals ongoing disease activity and may warrant therapeutic adjustment. 1
• Use validated activity measures (e.g., SLEDAI) together with CBC, anti‑dsDNA titres, and complement levels to quantify disease activity. 1

Optimization of Current Therapies

Hydroxychloroquine

• Dose hydroxychloroquine at approximately 5 mg per kilogram of ideal body weight per day, not exceeding 400 mg daily. 1
• Measure hydroxychloroquine blood concentration; a target level > 0.6 mg/L confirms adherence and adequate exposure. 1
• Do not discontinue hydroxychloroquine unless a specific contraindication exists; stopping the drug increases the risk of disease flare by roughly 2.5‑fold. [2][1]

Belimumab

• Continue belimumab in patients with stable or moderately active SLE; discontinuation is not required solely because of fever. Evidence from multiple Arthritis & Rheumatology studies supports continuation. [3][4]5
• Allow a therapeutic trial period of 6–12 months to evaluate response, especially when renal outcomes are a concern. 1

Therapeutic Escalation When Lupus Activity Is Confirmed

Glucocorticoids

• For moderate to severe flares, give intravenous methylprednisolone pulses of 250–1000 mg per day for 1–3 days to achieve rapid control. 1
• Maintain oral prednisone (or equivalent) at ≤5–7.5 mg daily for maintenance to limit long‑term toxicity. 1
• Avoid prolonged continuous glucocorticoid doses > 7.5 mg daily because adverse‑event risk rises sharply above this threshold. 1

Conventional Immunosuppressants

• Add or intensify mycophenolate mofetil, azathioprine, or methotrexate to facilitate glucocorticoid tapering when disease activity persists despite belimumab. 1
• Consider rituximab for organ‑threatening or refractory disease. 1
• Use cyclophosphamide as rescue therapy for severe, organ‑threatening manifestations. 1

Management of Confirmed Infections

• Treat documented infections aggressively and, for severe infections, temporarily reduce or hold immunosuppressive agents. 1
• Continue hydroxychloroquine even during short‑course (≈5 days) antibiotic therapy for pneumonia, as experience from the COVID‑19 pandemic indicates safety. 2
• A temporary pause of belimumab may be considered in the setting of a serious active infection, although specific guideline recommendations are lacking. 5

Common Pitfalls

• Do not alter the therapeutic regimen prematurely; give the current treatment an adequate trial period before making modifications. 1
• Recognize that belimumab, especially when combined with other immunosuppressants, adds to infection risk; vigilant monitoring is essential. 1 (Note: the increased risk of opportunistic infections is acknowledged but not quantified in the cited sources.)

Escalation of Therapy in Systemic Lupus Erythematosus

Standard Background Therapy

• The combination of belimumab, hydroxychloroquine, and low‑dose oral prednisone (≤5 mg daily) is considered a standard regimen for adult SLE patients 6, 7.

Addition of Conventional Immunosuppressants

• To enable rapid glucocorticoid reduction, a conventional immunosuppressant—mycophenolate (2–3 g daily), azathioprine, or methotrexate—should be introduced concurrently with pulse steroids 6.
• When cost or drug availability is limiting, methotrexate or azathioprine may be preferred over mycophenolate 6.

Oral Prednisone Taper After Pulse Therapy

• Following intravenous methylprednisolone pulses, oral prednisone should be started at a maximum of 0.5–0.6 mg/kg daily (up to 40 mg) and tapered to ≤5 mg daily within 3–6 months 7.
• Maintaining prednisone doses >7.5 mg daily long‑term markedly raises the risk of infections, osteonecrosis, and irreversible organ damage 7.

Management of Fever in Systemic Lupus Erythematosus without Organ Involvement

Infection Exclusion Strategies

• Perform cytomegalovirus (CMV) testing in SLE patients receiving immunosuppressants such as Belimumab because opportunistic CMV infection can occur under this therapy. 8
• Assess for severe neutropenia (< 500 cells/µL), severe lymphopenia (< 500 cells/µL) and low IgG (< 500 mg/dL); these laboratory abnormalities are the principal risk factors for infections in SLE. 8
• Conduct tuberculosis screening according to local guidelines before intensifying immunosuppression, as latent TB reactivation is a concern in this population. 8

Hydroxychloroquine Continuation

• Do not discontinue hydroxychloroquine; stopping the drug increases the risk of SLE flare by approximately 2.5‑fold. 9

Belimumab Continuation and Low‑Dose Glucocorticoids

• Continue Belimumab in patients with stable or moderately active SLE; cessation solely because of fever is not justified. 10
• For moderate flares without organ involvement, consider oral prednisolone at ≤ 10 mg per day as the first escalation step. 10
• Maintain the current regimen of hydroxychloroquine + Belimumab in patients presenting with sub‑febrile fever and negative infection work‑up. 10

Follow‑Up and Monitoring

• Arrange close clinical follow‑up every 3–6 months, including complete blood count, serum creatinine, proteinuria assessment, complement C3/C4 levels, and anti‑dsDNA antibodies to detect evolving disease activity. 8